Teva scrambles to block approval for Biogen’s Copaxone rival

14.01.2013                      03.Schwat. 5773

Pharma-Inustrie:

Teva scrambles to block approval for Biogen's Copaxone rival

Files citizen's petition and warns that Biogen Idec itself revealed troubling information about potential side effects of MS therapy BG-12.

Teva Pharmaceutical Industries last month began an effort to block or at least delay the launch of a drug that would compete with its blockbuster drug Copaxone, an injectable treatment for multiple sclerosis. Teva filed a citizen's petition to prevent the U.S. Food and Drug Administration approving Biogen Idec's pill BG-12, also a therapy for multiple sclerosis, which is an incurable degenerative disease….